Perspective Therapeutics Inc (AMEX:CATX) has a beta value of 1.15 and has seen 0.47 million shares traded in the recent trading session. The company, currently valued at $151.80M, closed the recent trade at $2.05 per share which meant it gained $0.09 on the day or 4.59% during that session. The CATX stock price is -829.27% off its 52-week high price of $19.05 and 7.32% above the 52-week low of $1.90. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.67 million shares traded. The 3-month trading volume is 773.87K shares.
The consensus among analysts is that Perspective Therapeutics Inc (CATX) is Buy stock at the moment, with a recommendation rating of 1.14. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.27.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Sporting 4.59% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CATX stock price touched $2.05 or saw a rise of 14.76%. Year-to-date, Perspective Therapeutics Inc shares have moved -35.74%, while the 5-day performance has seen it change -9.69%. Over the past 30 days, the shares of Perspective Therapeutics Inc (AMEX:CATX) have changed -12.77%. Short interest in the company has seen 5.94 million shares shorted with days to cover at 10.36.
Wall Street analysts have a consensus price target for the stock at $21, which means that the shares’ value could jump 90.24% from the levels at last check today. The projected low price target is $20.0 while the price target rests at a high of $22.0. In that case, then, we find that the latest price level in today’s session is -973.17% off the targeted high while a plunge would see the stock gain -875.61% from the levels at last check today.
Perspective Therapeutics Inc (CATX) estimates and forecasts
The company’s shares have lost -84.64% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -58.25%.
8 analysts offering their estimates for the company have set an average revenue estimate of 136.17k for the current quarter. 8 have an estimated revenue figure of 110.21k for the next ending quarter. Year-ago sales stood 325k and 526k respectively for this quarter and the next, and analysts expect sales will shrink by -58.10% for the current quarter and -58.25% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -9.86% over the past 5 years. Earnings growth for 2025 is a modest -5.33% while over the next 5 years, the company’s earnings are expected to decrease by -9.76%.
CATX Dividends
Perspective Therapeutics Inc is expected to release its next earnings report on 2025-Mar-25 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Perspective Therapeutics Inc (AMEX:CATX)’s Major holders
Insiders own 18.63% of the company shares, while shares held by institutions stand at 64.38% with a share float percentage of 79.12%. Investors are also buoyed by the number of investors in a company, with Perspective Therapeutics Inc having a total of 185.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund. As of Dec 31, 2024, the former fund manager holds about 2.29% shares in the company for having 1.69 shares of worth $3.45 million while later fund manager owns 1.64 shares of worth $3.34 million as of Feb 28, 2025, which makes it owner of about 2.22% of company’s outstanding stock.
